average monthly weight loss on semaglutide first month of Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial average weight loss first month

Semaglutide behaves as a glucagon-like-peptide-1 receptor agonist that judiciously links to as well as ignites the glucagon-like-peptide-1 receptor, which is the supreme target for native glucagon-like-peptide-1

If concerns or new symptoms arise, a medical professional can offer tailored advice and alternative options if necessary

Some studies have demonstrated synergistic benefits of using HRT and GLP1 agonists like Ozempi

Tirzepatide which targets both GLP-1 and GIP receptors has shown even more dramatic early results: weight loss of 1020 kg and insulin dose reductions exceeding 30% in observational and phase 2 data, with improved CGM time in range